AKT1 and cholangiocarcinoma: At the molecular level, in AKT/YapS127A mice, PD901 treatment resulted in the decreased expression of cell cycle proteins, including Cyclin A1 and cyclin D (Fig. 6b), whereas in K-Ras/NICD CCA model, PD901 treatment did not significantly alter the levels of these proteins10.